AmbrusJ. L.: Fibrinogen degradation products in children with renal disease. N. Y. State J. Med., 4; 1396 (1974).
2.
AstedtB., MattssonW.: Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. Acta Med. Scand., 210; 491 (1977).
3.
CaggianoS.: Comunicazione a « La settimana medica degli ospedali », Fiuggi, maggio 1979.
4.
ChristmanJ. Aos G.: Purification and charachterization of a cellular fibrinolytic factor associated with oncogenic transformation: the plasminogen activator from SV-40-Transformed hamster cells. Biochim. Biophys. Acta, 340; 339 (1974).
EliasG. E., ShuklaS. K.: Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer, 36; 29 (1975).
7.
MinkJ. B., AmbrusJ.: A diagrammatic explanation of the different coagulation processes as they occur around the tumor cells. Comunicazione personale (1975).
8.
O'MearaR. A.: Coagulative properties of cancers. Irish J. Med. Sci., 394; 474 (1958).
9.
OssowskyL., UnkelessJ. C.: An enzymatic function associated with transformed fibroblasts by oncogenic viruses. J. Exp. Med., 137; 112 (1973).
10.
RifkinD., LoebJ.: Properties of plasminogen activators formed by neoplastic human cell cultures. J. Exp. Med., 139; 1317 (1974).
11.
WajsmanZ., WilliamsP. D.: Further study of fibrinogen degradation products in bladder cancer detection. Urology, 10; (1978).
